Physician profile
John R Herring
NPI 1295747566
$1,089.60
in general payments reported to CMS, 2019-2025
20 companies · $244 in 2025
The $244 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $51.29 · 2022: $256 · 2023: $242 · 2024: $297 · 2025: $244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $682 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $682.05 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $239.01 | 2022-2024 | Myrbetriq |
| Astrazeneca Pharmaceuticals LP | $138.58 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Abbott Laboratories | $116.86 | 2024-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $108.06 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Novo Nordisk INC | $96.78 | 2024-2025 | Ozempic, Rybelsus |
| Lucid Diagnostics INC. | $63.05 | 2022 | |
| Pfizer INC. | $58.40 | 2022-2025 | |
| Abbvie INC. | $39.73 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $31.63 | 2022-2023 | Eliquis |
| Idorsia Pharmaceuticals US INC | $29.09 | 2022-2023 | Quviviq |
| Lilly USA, LLC | $27.72 | 2022-2024 | Mounjaro |
| Amgen INC. | $25.87 | 2023 | Prolia, Evenity |
| Viatris Specialty LLC | $18.62 | 2025 | Yupelri |
| Scilex Pharmaceuticals INC. | $15.70 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.63 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $14.58 | 2025 | Cologuard Collection Kit |
| Supernus Pharmaceuticals, INC. | $13.82 | 2022 | |
| Sumitomo Pharma America, INC. | $13.28 | 2024 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $13.16 | 2023 | |
| Novartis Pharmaceuticals Corporation | $11.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Herring listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.